Table 4
Differences in diisocyanate OA between those developing symptoms 1980–86 and 1987–93
| 1980–86 | 1987–93 | p Value | |
|---|---|---|---|
| *Number with information in the file. | |||
| n | 137 | 288 | |
| Age (y, mean (median)) | 40 (38.3) | 36 (33.9) | 0.002 |
| Male (%) | 72 | 55 | 0.001 |
| Exposure after onset of symptoms (y, mean (SD (median))) | 3.03 (3.92 (1.3) | 2.06 (3.17 (0.83) | 0.014 |
| Use of inhaled steroids (%) | 41 | 25 | 0.003 |
| FEV1 predicted (%, mean (SD (median))) | 96 (24 (100) | 98 (21 (99) | NS |
| VC predicted (%, mean (SD (median))) | 104 (21 (106) | 102 (17 (103) | NS |
| FEF50 predicted (%, mean (SD (median))) | 76 (40 (72.2) | 88 (33 (90.3) | 0.03 |
| FEF25 predicted (%, mean (SD (median))) | 71 (54 (58.8) | 75 (42 (67.2) | NS |
| Actual FEV1/VC (%, mean (median)) | 72 (73.9) | 77 (78.5) | 0.0003 |
| Methacholine PC20 during work period (mg/ml, mean (SD (median))) | 4.9 (11.1 (0.97)) (42)* | 4.4 (11.8 (0.8)) (59)* | NS |
| Methacholine PC20 off work (mg/ml, mean (SD (median))) | 13.2 (18.3 (6.0)) (77)* | 20.8 (25.3 (8.0)) (162)* | 0.02 |
